Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSHUA S JACOBS

Allopathic & Osteopathic Physicians Allergy & Immunology Allergy

NPI
1215920673
CMS profile
54402
Location
WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$314,248.30

453 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 8 of 10; records 351–400 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSHUA S JACOBS

NPI 1215920673 · CMS profile ID 54402

Allopathic & Osteopathic Physicians / Allergy & Immunology / Allergy

WALNUT CREEK, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 10; records 351–400 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 10; records 351–400 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 10; records 351–400 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOSHUA S JACOBS, NPI 1215920673, CMS profile ID 54402, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 10; records 351–400 of 453 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215920673?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

453 matching records · $314,248.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 453 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 453.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $86.8904/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398363 CMS
Regeneron Healthcare Solutions, Inc. $76.9704/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398365 CMS
Regeneron Healthcare Solutions, Inc. $296.4204/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398367 CMS
Shire North American Group Inc $21.1304/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846143 CMS
Teva Pharmaceuticals USA, Inc. $317.5204/09/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863451 CMS
Teva Pharmaceuticals USA, Inc. $4,040.0004/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863445 CMS
Regeneron Healthcare Solutions, Inc. $37.7504/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398359 CMS
Teva Pharmaceuticals USA, Inc. $2.2604/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697809191 CMS
Teva Pharmaceuticals USA, Inc. $61.1804/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863497 CMS
GlaxoSmithKline, LLC. $2.0004/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671487793 CMS
Shire North American Group Inc $122.0803/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846141 CMS
Shire North American Group Inc $4,125.0003/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846135 CMS
Shire North American Group Inc $40.3403/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846137 CMS
Shire North American Group Inc $75.8103/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846139 CMS
AstraZeneca Pharmaceuticals LP $40.3403/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685649617 CMS
Teva Pharmaceuticals USA, Inc. $6,000.0003/27/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697851121 CMS
Shire North American Group Inc $20.1903/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846133 CMS
Shire North American Group Inc $4,125.0003/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846131 CMS
AstraZeneca Pharmaceuticals LP $21.2803/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685469659 CMS
AstraZeneca Pharmaceuticals LP $43.5003/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685686415 CMS
Teva Pharmaceuticals USA, Inc. $6,000.0003/20/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697852121 CMS
Teva Pharmaceuticals USA, Inc. $520.6903/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697851129 CMS
Teva Pharmaceuticals USA, Inc. $520.6903/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697852119 CMS
Teva Pharmaceuticals USA, Inc. $11.6503/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697852123 CMS
Teva Pharmaceuticals USA, Inc. $78.0003/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697852125 CMS
Teva Pharmaceuticals USA, Inc. $44.0803/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697852127 CMS
Kaleo, Inc. $18.1103/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693185739 CMS
Teva Pharmaceuticals USA, Inc. $31.3503/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697675169 CMS
Teva Pharmaceuticals USA, Inc. $152.9003/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697774941 CMS
Teva Pharmaceuticals USA, Inc. $437.9303/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697824713 CMS
Shire North American Group Inc $49.8303/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846129 CMS
Genentech USA, Inc. $24.2003/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681176957 CMS
Shire North American Group Inc $4.7503/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846127 CMS
PFIZER INC. $13.2903/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672961217 CMS
Teva Pharmaceuticals USA, Inc. $86.0803/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863401 CMS
Teva Pharmaceuticals USA, Inc. $19.1703/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863405 CMS
Regeneron Healthcare Solutions, Inc. $35.2503/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398355 CMS
Regeneron Healthcare Solutions, Inc. $315.0503/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398357 CMS
Teva Pharmaceuticals USA, Inc. $16.0503/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697690809 CMS
GlaxoSmithKline, LLC. $10.9403/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671427021 CMS
Novartis Pharmaceuticals Corporation $20.5603/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659633323 CMS
Shire North American Group Inc $62.6003/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637846125 CMS
AstraZeneca Pharmaceuticals LP $1,400.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685659747 CMS
Teva Pharmaceuticals USA, Inc. $4,040.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863397 CMS
Teva Pharmaceuticals USA, Inc. $234.8203/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697863399 CMS
Regeneron Healthcare Solutions, Inc. $25.0003/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398345 CMS
Regeneron Healthcare Solutions, Inc. $162.4003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398347 CMS
Regeneron Healthcare Solutions, Inc. $6.0003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398349 CMS
Regeneron Healthcare Solutions, Inc. $66.7003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398351 CMS
Regeneron Healthcare Solutions, Inc. $6.0003/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673398353 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $314,248.30 453
PY2020 $119,758.85 189
PY2021 $117,754.14 256
PY2022 $222,306.53 336
PY2023 $246,372.21 414
PY2024 $248,557.09 383
PY2025 $250,306.43 392

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $385,852.83 52
PY2024 Recipient $4,500.00 1
PY2024 Principal investigator $448,685.78 51
PY2023 Recipient $12,257.82 18
PY2023 Principal investigator $532,990.69 118
PY2022 Principal investigator $617,668.37 129
PY2021 Recipient $6,631.04 2
PY2021 Principal investigator $794,953.96 186
PY2020 Recipient $600.56 2
PY2020 Principal investigator $362,418.42 76
PY2019 Principal investigator $452,657.15 128

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $10,699.09 12/11/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246791464
Principal investigator 1 CSL Behring $1,974.00 11/17/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673452
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 11/07/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049323
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 10/28/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192143445
Principal investigator 1 Novartis Pharmaceuticals Corporation $7,589.80 10/23/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190310454
Principal investigator 1 CSL Behring $2,465.00 10/22/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673450
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 10/22/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,643.30 10/16/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223287035
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,376.59 10/08/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190306383
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 10/03/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049319
Principal investigator 1 CSL Behring $1,974.00 08/18/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673448
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,854.06 08/14/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190310456
Principal investigator 1 Ionis Pharmaceuticals, Inc. $30,521.64 08/08/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH
IS744CS7 No dispute reported 06/30/2026 1246786373
Principal investigator 1 CSL Behring $171.24 07/31/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673384
Principal investigator 1 CSL Behring $174.00 07/30/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673382
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,189.70 07/22/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,143.80 07/22/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282918
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,189.70 07/17/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223282784
Principal investigator 1 CSL Behring $9,870.00 07/14/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673440
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,611.63 07/09/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyposis WAYPOINT No dispute reported 06/30/2026 1185552291
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,332.00 07/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310452
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,804.40 06/24/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281754
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,804.40 06/19/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281632
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,500.00 06/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281134
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,520.00 06/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,208.00 06/12/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223281146
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 06/06/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,601.00 06/05/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280764
Principal investigator 1 PFIZER INC. $11,750.00 06/04/2025 Non-covered Recipient Entity
Allergy Asthma Clinical Research
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228790236
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 06/01/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH
LONG-TERM SAFETY AND TOLERABILITY OF TAK-881 IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280520
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,601.00 05/22/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223280114
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,202.00 05/15/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223279800
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $175.00 05/01/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278728
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 04/29/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244049315
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,527.90 04/22/2025 Non-covered Recipient Entity
ALLERGY ASTHMA CLINICAL RESEARCH
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190299759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,202.00 04/17/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223278184
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,750.00 04/11/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552293
Principal investigator 1 CSL Behring $76.00 04/11/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673422
Principal investigator 1 CSL Behring $377.22 04/09/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673380
Principal investigator 1 CSL Behring $118.24 04/07/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673378
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17.65 03/26/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045444
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $21.41 03/26/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045446
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $72.80 03/26/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045448
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,353.30 03/20/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223276879
Principal investigator 1 CSL Behring $85,432.20 03/18/2025 Non-covered Recipient Entity
Allergy And Asthma Clinical Research
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252673454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,151.30 02/20/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
MULTICENTER, PROSPECTIVE, OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS (PK), SAFETY, TOLERABILITY OF TAK-881-3001 IN PRIMARY IMMUNODEFICIENCY DISEASES (PIDD) No dispute reported 06/30/2026 1223275419
Principal investigator 1 Novartis Pharmaceuticals Corporation $65,178.44 01/30/2025 Non-covered Recipient Entity
ALLERGY ASTHMA CLINICAL RESEARCH
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190299755
Principal investigator 1 Amgen Inc. $17,616.56 01/27/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246638957
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,478.32 01/24/2025 Non-covered Recipient Entity
ALLERGY & ASTHMA CLINICAL RESEARCH INC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552297
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,514.93 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH INCORPORATION
A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy No dispute reported 06/30/2026 1190302401
Principal investigator 1 Novartis Pharmaceuticals Corporation $225.39 01/01/2025 Non-covered Recipient Entity
ALLERGY AND ASTHMA CLINICAL RESEARCH INCORPORATION
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190302403

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $4,891.07 1
PY2025 Value of interest $4,891.07 1
PY2024 Amount invested $4,891.07 1
PY2024 Value of interest $4,891.07 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2024–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Consortium of Independent Immunology Clinics, LLC $4,891.07 $4,891.07 n/a Physician Covered Recipient No dispute reported 06/30/2026 1224798458
PY2024 Consortium of Independent Immunology Clinics, LLC $4,891.07 $4,891.07 n/a Physician Covered Recipient No dispute reported 06/30/2026 1147099050